sb 216763 has been researched along with Experimental Radiation Injuries in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Castle, KD; Chao, NJ; Kirsch, DG; Lee, CL; Lento, WE | 1 |
| Dickey, AK; Geng, L; Hallahan, DE; Thotala, DK; Yazlovitskaya, EM | 1 |
2 other study(ies) available for sb 216763 and Experimental Radiation Injuries
| Article | Year |
|---|---|
Inhibiting glycogen synthase kinase-3 mitigates the hematopoietic acute radiation syndrome in mice.
Topics: Acute Radiation Syndrome; Aminophenols; Animals; Apoptosis; Bone Marrow; Cells, Cultured; Colony-Forming Units Assay; Drug Evaluation, Preclinical; Glycogen Synthase Kinase 3; Hematopoiesis; Hematopoietic Stem Cells; Indoles; Injections, Subcutaneous; Maleimides; Mice; Mice, Inbred C57BL; Oximes; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Radiation Injuries, Experimental; Whole-Body Irradiation | 2014 |
A new class of molecular targeted radioprotectors: GSK-3beta inhibitors.
Topics: Aminophenols; Animals; Apoptosis; bcl-2-Associated X Protein; beta Catenin; Caspase 3; Cell Line; Cell Survival; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; In Situ Nick-End Labeling; Indoles; Intestines; Maleimides; Mice; Mice, Inbred C57BL; Radiation Injuries, Experimental; Radiation-Protective Agents; Rats | 2010 |